Charles Schwab’s Acura Pharmaceuticals ACUR Stock Holding History

Charles Schwab’s Portfolio ACUR Stock Details ACUR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-4,180	Closed	-$21K	–	3106
2015 Q2	$21K	Hold	4,180	–	–	﹤0.01%	3085
2015 Q1	$17K	Hold	4,180	–	–	﹤0.01%	3078
2014 Q4	$10K	Hold	4,180	–	–	﹤0.01%	3106
2014 Q3	$17K	Hold	4,180	–	–	﹤0.01%	3067
2014 Q2	$23K	Hold	4,180	–	–	﹤0.01%	3080
2014 Q1	$31K	Hold	4,180	–	–	﹤0.01%	3061
2013 Q4	$35K	Hold	4,180	–	–	﹤0.01%	3073
2013 Q3	$40K	Hold	4,180	–	–	﹤0.01%	3051
2013 Q2	$47K	Buy	+4,180	New	+$47.2K	﹤0.01%	3035

Other funds holding ACUR

EWM

Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SIM

Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return

FWP

FAS Wealth Partners Leawood, Kansas $1.61B AUM 19.97% 1-Year Est. Return

Charles Schwab's ACUR Position: Q3 2015 in Review

Charles Schwab sold out of Acura Pharmaceuticals (ACUR) in Q3 2015, closing a stake of 4,180 shares — an estimated $21K sold.

Charles Schwab first reported a position in ACUR in Q2 2013 and held it in 9 quarters. The position peaked at $47K in Q2 2013. 22 funds tracked by Wall St. Rank hold ACUR as of Q3 2015.

Charles Schwab reported no remaining Acura Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
Charles Schwab sold 4,180 Acura Pharmaceuticals shares in Q3 2015, an estimated $21K.
Charles Schwab first reported a position in Acura Pharmaceuticals in Q2 2013 and held it in 9 quarters.
Charles Schwab's Acura Pharmaceuticals position peaked at $47K in Q2 2013.
22 funds tracked by Wall St. Rank held Acura Pharmaceuticals as of Q3 2015.

Based on Charles Schwab's 13F filing for Q3 2015, filed 13 Nov 2015.